Lowell L. Hart, MD, FACP
- Associate Professor, Hematology and Oncology
Lowell L. Hart, MD, FACP
Research Interests
- Phase 1 Clinical Trials
- Lung Cancer
- Breast Cancer
- Education
- MD, State University of New York at Syracuse, 1980
- Residency
- Internal Medicine, University of Miami School of Medicine, 1983
- Fellowship
- Pediatric Hematology and Oncology, Duke University Medical Center, 1986
- Board Certifications
- American Board of Internal Medicine, Hematology
- American Board of Internal Medicine, Internal Medicine
- American Board of Internal Medicine, Medical Oncology
- Positions
- Associate Professor, Hematology and Oncology
- Departments and Affiliations
- Hematology and Oncology
- Comprehensive Cancer Center
Research
- Phase I/II trial of exemestane, ribociclib, and everolimus in women with HR+/HER2- advanced breast cancer after progression on CDK4/6 inhibitors (TRINITI-1). Bardia A, Hurvitz SA, DeMichele A, Clark AS, Zelnak A, Yardley D, Karuturi MS, Sanft T, Blau S, Hart L, Ma CX, Rugo HS, Purkayastha D, Moulder-Thompson S. Clin Cancer Res. 2021 Mar;
- Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer. Li C, Hart L, Owonikoko TK, Aljumaily R, Rocha Lima CM, Conkling PR, Webb RT, Jotte RM, Schuster S, Edenfield WJ, Smith DA, Sale M, Roberts PJ, Malik RK, Sorrentino JA. Cancer Chemother Pharmacol. 2021 May; 87(5):689-700.
- The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+?and androgen receptor-positive metastatic or locally advanced breast cancer. Wardley A, Cortes J, Provencher L, Miller K, Chien AJ, Rugo HS, Steinberg J, Sugg J, Tudor IC, Huizing M, Young R, Abramson V, Bose R, Hart L, Chan S, Cameron D, Wright GS, Graas MP, Neven P, Rocca A, Russo S, Krop IE. Breast Cancer Res Treat. 2021 May; 187(1):155-165.
- A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose-expansion cohort. Berdeja JG, Gregory TK, Faber EA, Hart LL, Mace JR, Arrowsmith ER, Flinn IW, Matous JV. Am J Hematol. 2021 04; 96(4):428-435.
- Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled Phase II trial. Daniel D, Kuchava V, Bondarenko I, Ivashchuk O, Reddy S, Jaal J, Kudaba I, Hart L, Matitashvili A, Pritchett Y, Morris SR, Sorrentino JA, Antal JM, Goldschmidt J. Int J Cancer. 2020 Dec;